Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing

Cellectar Biosciences, Inc.

CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.
CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.
CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.
No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.
Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.